| Q38377743 | Adjunctive Oral Voriconazole Treatment of Fusarium Keratitis: A Secondary Analysis From the Mycotic Ulcer Treatment Trial II. |
| Q98779119 | Antimycotic Activity of Ozonized Oil in Liposome Eye Drops against Candida spp |
| Q46586805 | Aqueous humor concentration of voriconazole after topical administration in rabbits |
| Q33899260 | Aspergillus fumigatus scleritis associated with monoclonal gammopathy of undetermined significance |
| Q34005900 | Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis |
| Q93338789 | Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections |
| Q26796727 | Cladosporium keratitis - a case report and literature review |
| Q34936576 | Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. |
| Q37750488 | Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis |
| Q35964636 | Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis |
| Q36729111 | Corneal Transplant Infection due to Alternaria alternata: A Case Report. |
| Q35270872 | Cytotoxicity of voriconazole on cultured human corneal endothelial cells |
| Q38385726 | Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Clinical Trial |
| Q33705648 | Effect of voriconazole and ultraviolet-A combination therapy compared to voriconazole single treatment on Fusarium solani fungal keratitis |
| Q42201729 | Effective treatment of invasive Aspergillus fumigatus infection using combinations of topical and systemic antifungals in a severely burned patient |
| Q93034100 | Efficacy of Luliconazole Against Broad-Range Filamentous Fungi Including Fusarium solani Species Complex Causing Fungal Keratitis |
| Q36933883 | Expert prior elicitation and Bayesian analysis of the Mycotic Ulcer Treatment Trial I. |
| Q38766818 | Fungal Infections in Boston Keratoprosthesis Patients: Lessons Learned and Novel Developments on the Horizon |
| Q46876260 | Fungal keratitis caused by Scedosporium apiospermum |
| Q49033777 | Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis |
| Q37358728 | Open-Label Study of Absorption and Clearance of 1% Voriconazole Eye Drops. |
| Q36964173 | Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial |
| Q53090260 | Performance evaluation of enzyme immunoassay for voriconazole therapeutic drug monitoring with automated clinical chemistry analyzers. |
| Q41842028 | Pharmacokinetics of intracameral voriconazole injection |
| Q43194325 | Preparation and stability of voriconazole eye drop solution |
| Q37247754 | Prospective open-label study of the administration of two-percent voriconazole eye drops |
| Q41449739 | Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial. |
| Q50082031 | Recent advances in topical nano drug-delivery systems for the anterior ocular segment. |
| Q46976938 | Scedosporium apiospermum traumatic endophthalmitis successfully treated with voriconazole |
| Q42854412 | Single and Multidose Ocular Kinetics and Stability Analysis of Extemporaneous Formulation of Topical Voriconazole in Humans |
| Q43295186 | Stability of extemporaneously prepared voriconazole ophthalmic solution |
| Q41010354 | Strategies for antifungal treatment failure in intensive care units |
| Q41584821 | The characteristics of keratomycosis by Beauveria bassiana and its successful treatment with antimycotic agents |
| Q42751535 | The role of second-generation antifungal triazoles for treatment of the endemic mycoses. |
| Q37789598 | Update on Fungal Keratitis From 1999 to 2008 |
| Q41931288 | Update on the Management of Infectious Keratitis |
| Q37084273 | Voriconazole for the treatment of refractory Aspergillus fumigatus keratitis |